Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1974-1978

  Wenisch, Judith M ^a   Schmid, Daniela ^b   Kuo, Hung Wei ^b   Allerberger, Franz ^b,c   Michl, Verena ^d   Tesik, Philip ^d   Tucek, Gerhard ^d   Laferl, Hermann ^d   Wenisch, Christoph ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CAUSE OF DEATH; CHARLSON COMOROBIDITY INDEX; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON PERFORATION; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HOSPITAL PATIENT; HUMAN; INFECTION COMPLICATION; MALE; MORTALITY; OBSERVATIONAL STUDY; PARALYTIC ILEUS; PERITONITIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; SCORING SYSTEM; SEPSIS; TOXIC MEGACOLON; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METRONIDAZOLE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; RISK; SEX FACTORS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84858627904     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05647-11     Document Type: Article

References (19)

1. Bartlett JG. 2006. New drugs for Clostridium difficile infection. Clin. Infect. Dis. 43:428-431. (Pubitemid 44157149)
2. Bauer MP, Kuijper EJ, van Dissel JT. 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15:1067-1079.
3. Bauer MP, et al. 2011. Clostridium difficile infection in Europe: a hospital- based survey. Lancet 377:63-73.
4. Bauer MP, et al. 2008. Recurrence of Clostridium difficile-associated diarrhoea prevented by the administration of a whey concentrate from specifically immunised cows; prospective study. Ned. Tijdschr. Geneeskd. 152:1919-1926. (In Dutch.)
5. Bolton RP, Culshaw MA. 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27:1169-1172. (Pubitemid 16002615)
6. Cohen SH, et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
7. Freeman J, et al. 2010. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23:529-549.
8. Johnson S, et al. 1992. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann. Intern. Med. 117:297-302.
9. Kling PA, Burman LG. 1989. Serum and tissue pharmacokinetics of intravenous metronidazole in surgical patients. Acta Chir. Scand. 155: 347-350. (Pubitemid 19283706)
10. Kuijper EJ, van Dissel JT. 2008. Spectrum of Clostridium difficile infections outside health care facilities. CMAJ 179:747-748.
11. Kuijper EJ, Wilcox MH. 2008. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin. Infect. Dis. 47: 63-65. (Pubitemid 351920589)
12. Lamp KC, Freeman CD, Klutman NE, Lacy MK. 1999. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. 36:353-373. (Pubitemid 29261511)
13. Martin C, et al. 1991. Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery. Antimicrob. Agents Chemother. 35:2602-2605.
14. Mattila J, Mannisto PT, Mantyla R, Nykanen S, Lamminsivu U. 1983. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob. Agents Chemother. 23:721-725. (Pubitemid 13087010)
15. McDonald LC, et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441. (Pubitemid 41770164)
16. Sabin CA. 2010. Cohort studies: to what extent can they inform treatment guidelines? Curr. Opin. Infect. Dis. 23:15-20.
17. Thiercelin JF, et al. 1984. Metronidazole kinetics and bioavailability in patients undergoing gastrointestinal surgery. Clin. Pharmacol. Ther. 35: 510-519. (Pubitemid 14133492)
18. Warny M, et al. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084. (Pubitemid 41338761)
19. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile- associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307. (Pubitemid 47101025)